Shares in UK biotech Valirx were up sharply this morning after its lead drug VAL201 showed evidence of efficacy in advanced prostate cancer in its first clinical trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,